Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CLL according to the National Cancer Institute (NCI) criteria or SLL according to the World Health Organization (WHO) criteria, including previous documentation of:~* Biopsy-proven SLL~* Diagnosis of CLL according to NCI working group criteria as evidenced by all of the following:~  * Peripheral blood lymphocyte count of \> 5,000/mm\^3 consisting of small to moderate size lymphocytes, with \< 55% prolymphocytes~ * Immunophenotyping consistent with CLL defined as:~    * The predominant population of lymphocytes share both B-cell antigens (CD19, CD20 \[typically dim expression\], or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.)~   * Clonality as evidenced by kappa or lambda light chain expression (typically dim immunoglobulin expression)~   * Note: splenomegaly, hepatomegaly, or lymphadenopathy are not required for the diagnosis of CLL~ * Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative FISH analysis for t(11;14)(immunoglobulin heavy \[IgH\]/cyclin D1 \[CCND1\]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for CCND1 on involved tissue biopsy~* Patients must be previously untreated and meet at least one of the following indications for chemotherapy:~  * Evidence of progressive marrow failure as manifested by the development of or worsening anemia (=\< 11 g/dl) and/or thrombocytopenia (=\< 100,000/mm\^3) not due to autoimmune disease~ * Symptomatic or progressive lymphadenopathy, splenomegaly or hepatomegaly~ * One or more of the following disease-related symptoms:~    * Weight loss \> 10% within the previous 6 months~   * Extreme fatigue attributed to CLL~   * Fevers \> 100.5 degree Fahrenheit for 2 weeks without evidence of infection~   * Drenching night sweats without evidence of infection~ * Progressive lymphocytosis due to CLL with an increase of \> 50% over a two-month period or an anticipated doubling time of less than six months~    * Prior chemotherapy or monoclonal antibody based therapy for treatment of CLL will be considered prior therapy; nutraceutical treatments with no established benefit in CLL (such as epigallocatechin gallate \[EGCG\], found in green tea or other herbal treatments) will not be considered prior treatment~   * Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease are not sufficient for protocol therapy~* Serum creatinine =\< 1.5 x upper normal levels (UNL)~* Total bilirubin =\< 1.5 x UNL unless due to Gilbert's disease; if total bilirubin is \> 1.5 x UNL, a direct bilirubin should be performed and must be \< 1.5 mg/dL for Gilbert's to be diagnosed~* Aspartate aminotransferase (AST) =\< 3.0 x UNL and alanine aminotransferase (ALT) =\< 3.0 x UNL (unless due to hemolysis or CLL)~* Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1, or 2~* Willingness to provide blood samples as required~* Able to adhere to the study visit schedule and other protocol requirements~Exclusion Criteria:~* Any of the following comorbid conditions:~  * New York Heart Association Class III or IV heart disease~ * Recent myocardial infarction (\< 1 month)~ * Uncontrolled infection~ * Infection with the human immunodeficiency virus (HIV/acquired immunodeficiency syndrome \[AIDS\])~ * Infection with known chronic, active Hepatitis C~ * Positive serology for hepatitis B (HB) defined as a positive test for HB surface antigen (HBsAg); in addition, if negative for HBsAg but HB core antibody (HBcAb) positive (regardless of HBsAb status), a HB deoxyribonucleic acid (DNA) test will be performed and if positive the subject will be excluded~* Pregnant women~* Nursing women~* Men or women of childbearing potential who are unwilling to employ adequate contraception~* Other active primary malignancy requiring treatment or limiting survival to =\< 2 years~* Any radiation therapy =\< 4 weeks prior to registration~* Any major surgery =\< 4 weeks prior to registration~* Current use of corticosteroids; EXCEPTION: low doses of steroids (\< 10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical conditions; Note: previous use of corticosteroids is allowed~* Active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment; patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (PCO, closed to accrual as of 8/23/2011) (Type: EXPERIMENTAL): Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm B (PCO with ofatumumab consolidation) (Type: EXPERIMENTAL): Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).